Investigation of the Structural Quality of Bone and Cartilage Repair Following Cell Therapy
Lead Research Organisation:
Keele University
Department Name: Inst for Science and Tech in Medicine
Abstract
Using the body's own cells, known as "cell therapy", is an attractive way to repair worn or damaged body parts. For many years, our Centre has help patients who have knee cartilage damage by using cartilage cells to help repair areas of damaged cartilage. A handful of small studies in humans have shown that stem cells could also be used, not only to help repair cartilage, but also to help repair the underlying bone. The two cells types in combination might help even better. To find out, the charity Arthritis Research UK is funding a clinical trial in our Centre to compare cartilage cells versus stem cells versus the two cell types together.
This trial forms a unique opportunity to find out not only which type of cell is better, but also how the cells help repair and which patients are best suited for this treatment. This grant application asks for funding to help us finding out how these different cell types, both alone and in combination, behave inside the joint. We especially like to know how they go on to produce cartilage and bone, arranged in the right way, with the right properties to improve knee function. It will also help us to find out beforehand which cell types are best for which patient, or perhaps identify patients beforehand for whom cell therapy is not a good option. If so, it would save them pinning their hopes on this treatment.
Our clinical experience has shown us that the full benefit of cell therapy is seen around one year after cell implantation. At this time point we plan to use a range of techniques to identify and quantify the different types of repair tissue produced. These techniques include Magnetic Resonance Imaging (MRI), visual inspection of the joint itself during knee joint surgery, and examining biopsies of repair tissue down the microscope. MRI can show us how much new cartilage and bone have formed, if the new tissue fills the whole damaged area, how smooth the surface of the cartilage is and how well attached it is to the adjacent normal cartilage. Histology using the microscope and other specialised techniques can show the actual molecules which are present, how they are arranged and how the cells are behaving. We will be able to compare cartilage cells and stem cells and see if one type is better than the other at forming good quality cartilage and/or bone.
To identify patients for whom cell therapy is not a good option, we will measure which of the thousands of genes are switched on in the cells that we implant. By comparing between the genes and the measurements we do on the patients at one year, we hope to find gene patterns that identify such patients.
This trial forms a unique opportunity to find out not only which type of cell is better, but also how the cells help repair and which patients are best suited for this treatment. This grant application asks for funding to help us finding out how these different cell types, both alone and in combination, behave inside the joint. We especially like to know how they go on to produce cartilage and bone, arranged in the right way, with the right properties to improve knee function. It will also help us to find out beforehand which cell types are best for which patient, or perhaps identify patients beforehand for whom cell therapy is not a good option. If so, it would save them pinning their hopes on this treatment.
Our clinical experience has shown us that the full benefit of cell therapy is seen around one year after cell implantation. At this time point we plan to use a range of techniques to identify and quantify the different types of repair tissue produced. These techniques include Magnetic Resonance Imaging (MRI), visual inspection of the joint itself during knee joint surgery, and examining biopsies of repair tissue down the microscope. MRI can show us how much new cartilage and bone have formed, if the new tissue fills the whole damaged area, how smooth the surface of the cartilage is and how well attached it is to the adjacent normal cartilage. Histology using the microscope and other specialised techniques can show the actual molecules which are present, how they are arranged and how the cells are behaving. We will be able to compare cartilage cells and stem cells and see if one type is better than the other at forming good quality cartilage and/or bone.
To identify patients for whom cell therapy is not a good option, we will measure which of the thousands of genes are switched on in the cells that we implant. By comparing between the genes and the measurements we do on the patients at one year, we hope to find gene patterns that identify such patients.
Technical Summary
We aim to study the structural quality of bone and cartilage repair tissue in degenerate or injured knee joints following cell therapy with either chondrocytes and/or mesenchymal stromal cells. We have already been granted funding by Arthritis Research UK to carry out a randomised controlled trial in 114 subjects to compare the clinical benefit of the three cell therapy strategies (Autologous Stem cells, Chondrocytes Or the Two, ASCOT). The work described in this proposal would require the subjects recruited into the ASCOT trial to undergo 3 additional sets of investigations: imaging, arthroscopy and histological assessments at approximately 1 year after the cell implantation. The main objectives of this 'add-on' study would be (1) To determine the structural quality of repair tissue which forms in these patients, using MRI/CT, visual assessment and histology (including immunohistochemistry). This will allow us to look at a whole range of outcomes including: repair cartilage thickness, volume, signal intensity, surface integrity, morphology and biochemical content and subchondral bone structure including the presence of inflammation, oedema and cysts, determination of cortical integrity, bone densitometry, macroscopic appearance of the repair site and the adjacent tissues. (2) To relate structural quality of repair to the clinical outcome of the patients, the characteristics of the cells being implanted and the environment they will be implanted into (cell characterisation and biomarker analysis funded elsewhere). (3) To investigate whether MRI or CT can be used in aiding the selection of patients who will benefit from ACI. (4) To trial an FT-IRIS probe to investigate the integrity, composition and organisation of the repair tissue in a less invasive way than by biopsy. (5) To help to elucidate which cell types are most appropriate for treating joints with osteochondral defects or osteoarthritis.
Planned Impact
Workers in academia will benefit directly. These benefits have been described in the above section "Academic beneficiaries".
The most direct beneficiaries from the research will be patients with cartilage and bone defects and/or early osteoarthritis. The data from the research, combined with the primary outcome of the trial, will demonstrate to the patients and their doctor or surgeon which type of cell therapy gives most benefit in the short term and leads to cartilage-like tissue that is most likely to provide long-term benefits.
Practicing surgeons and doctors will also benefit from the proposed research. The data on histology and imaging from the proposed work will substantiate findings from the proposed trial, and increase trust in the trial results.
The public bodies NICE (National Institute for Health and Care Excellence) and the NHS will be beneficiaries of this work. Biopsy data plays an important role in the long-term models that NICE uses to determine cost-benefit of cell therapy. Without such data, long-term forecasting is more difficult. Autologous Chondrocyte Implantation (ACI) is currently available on the NHS as part of a clinical trial, pending further advice from NICE. A trial with biopsy will help NICE to analyze the cost-benefit of the three arms in the trial. The NICE advice will then help the NHS in their decision of providing cell therapy to cartilage patients.
Business and industry can benefit, especially if bone marrow stromal cells prove beneficial to cartilage patients. Although the trial uses autologous cells, allogeneic cells may provide similar benefits. Several companies are investigating the use of allogeneic mesenchymal stem cells. Companies involved in autologous cell culturing will also benefit by the extended evidence from the data on the efficacy of cell therapy to repair cartilage damage.
Another sector to benefit, in particular, will be charities involved with patients with joint disorders. Arthritis Research UK, one of those charities, funds the clinical trial to which this the current research proposal is attached. Arthritis Research UK is very interested in cartilage repair strategies, as demonstrated by their willingness to fund the clinical trial. The proposed research will enhance the conclusions from the trial, thus helping the charity in advising the public. Arthritis Care, another charity supporting people with arthritis, will also be interested in the research. Many of its members discuss the merits of cell therapy on their forums.
The most direct beneficiaries from the research will be patients with cartilage and bone defects and/or early osteoarthritis. The data from the research, combined with the primary outcome of the trial, will demonstrate to the patients and their doctor or surgeon which type of cell therapy gives most benefit in the short term and leads to cartilage-like tissue that is most likely to provide long-term benefits.
Practicing surgeons and doctors will also benefit from the proposed research. The data on histology and imaging from the proposed work will substantiate findings from the proposed trial, and increase trust in the trial results.
The public bodies NICE (National Institute for Health and Care Excellence) and the NHS will be beneficiaries of this work. Biopsy data plays an important role in the long-term models that NICE uses to determine cost-benefit of cell therapy. Without such data, long-term forecasting is more difficult. Autologous Chondrocyte Implantation (ACI) is currently available on the NHS as part of a clinical trial, pending further advice from NICE. A trial with biopsy will help NICE to analyze the cost-benefit of the three arms in the trial. The NICE advice will then help the NHS in their decision of providing cell therapy to cartilage patients.
Business and industry can benefit, especially if bone marrow stromal cells prove beneficial to cartilage patients. Although the trial uses autologous cells, allogeneic cells may provide similar benefits. Several companies are investigating the use of allogeneic mesenchymal stem cells. Companies involved in autologous cell culturing will also benefit by the extended evidence from the data on the efficacy of cell therapy to repair cartilage damage.
Another sector to benefit, in particular, will be charities involved with patients with joint disorders. Arthritis Research UK, one of those charities, funds the clinical trial to which this the current research proposal is attached. Arthritis Research UK is very interested in cartilage repair strategies, as demonstrated by their willingness to fund the clinical trial. The proposed research will enhance the conclusions from the trial, thus helping the charity in advising the public. Arthritis Care, another charity supporting people with arthritis, will also be interested in the research. Many of its members discuss the merits of cell therapy on their forums.
Publications
Wright KT
(2017)
The Absence of Detectable ADAMTS-4 (Aggrecanase-1) Activity in Synovial Fluid Is a Predictive Indicator of Autologous Chondrocyte Implantation Success.
in The American journal of sports medicine
Wang J
(2019)
Combined Autologous Chondrocyte and Bone Marrow Mesenchymal Stromal Cell Implantation in the Knee: An 8-year Follow Up of Two First-In-Man Cases
in Cell Transplantation
Toh WS
(2016)
Cellular senescence in aging and osteoarthritis.
in Acta orthopaedica
Ryd L
(2015)
Pre-Osteoarthritis: Definition and Diagnosis of an Elusive Clinical Entity.
in Cartilage
Roberts S
(2016)
Ageing in the musculoskeletal system.
in Acta orthopaedica
Roberts S
(2014)
Techniques in Cartilage Repair Surgery
Richardson JB
(2017)
Efficacy and safety of autologous cell therapies for knee cartilage defects (autologous stem cells, chondrocytes or the two): randomized controlled trial design.
in Regenerative medicine
Richardson J
(2014)
Techniques in Cartilage Repair Surgery
Perry J.
(2019)
HUMAN UMBILICAL CORD MESENCHYMAL STROMAL CELLS DO NOT EVOKE AN IMMUNE RESPONSE IN THE PARTIAL MEDIAL MENISCECTOMY MURINE MODEL OF OSTEOARTHRITIS
in OSTEOARTHRITIS AND CARTILAGE
Perry J
(2023)
Comparison of Knee Articular Cartilage Defect Size Between Measurements Obtained on Preoperative MRI Versus During Arthrotomy.
in Orthopaedic journal of sports medicine
Perry J
(2020)
Injected human umbilical cord-derived mesenchymal stromal cells do not appear to elicit an inflammatory response in a murine model of osteoarthritis.
in Osteoarthritis and cartilage open
Mennan C
(2020)
The use of technology in the subcategorisation of osteoarthritis: a Delphi study approach.
in Osteoarthritis and cartilage open
McCarthy HS
(2023)
Histological and Radiological Assessment of Endogenously Generated Repair Tissue In Vivo Following a Chondral Harvest.
in Cartilage
McCarthy HS
(2018)
Magnetic Resonance Imaging Parameters at 1 Year Correlate With Clinical Outcomes Up to 17 Years After Autologous Chondrocyte Implantation.
in Orthopaedic journal of sports medicine
McCarthy H. S.
(2019)
The natural repair of articular cartilage in humans: an immunohistological study
in INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Description | NICE Meeting Regarding ChondroCelect TA89 [ID686] 11 June 2014 |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | NICE Multiple Technology Appraisal (MTA) Re ACI TA89 [ID686] 10 February 2015 |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | NICE Multiple Technology Appraisal re ACI TA89 [ID686] 14 April 2015 |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | NICE Technology Assessment TA477 ACI for treating symptomatic articular cartilage defects of the knee |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | Recognises ACI as a clinical and fundable treatment within the NHS and in turn will improve clinical service delivery. |
URL | http://nice.org.uk/guidance/ta477 |
Description | NICE Technology Assessment TA477 ACI for treating symptomatic articular cartilage defects of the knee |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | Recognises ACI as a clinical and fundable treatment within the NHS and in turn will improve clinical service delivery. |
URL | http://nice.org.uk/guidance/ta477 |
Description | Setting up a standard for the identification of MSCs |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | The National Institute for Biological Standards and Control (NIBSC) approached our lab and asked if we would test a series of their MSC standards against our cells, in order to create standards for flow cytometry for therapeutic MSCs. This could have tremendous impact worldwide on what cells we are "allowed" to call MSCs. |
Description | Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2) |
Amount | £2,380,000 (GBP) |
Organisation | MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) |
Sector | Academic/University |
Country | United Kingdom |
Start |
Description | Assessing and Measuring the Quality of RNA for Research Studies in the RJAH Orthopaedic Hospital NHS Foundation Trust |
Amount | £21,983 (GBP) |
Organisation | Institute of Orthopaedics |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2019 |
Description | Cell therapy for the ankle |
Amount | £79,560 (GBP) |
Organisation | Institute of Orthopaedics |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 12/2023 |
Description | Extension to VA Grant 18480 Cell Therapy for Osteoarthritis (ASCOT) |
Amount | £24,650 (GBP) |
Funding ID | 18480 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2010 |
End | 04/2024 |
Description | Grant from Keele University to carry out a Market Analysis of ACI |
Amount | £10,000 (GBP) |
Organisation | Keele University |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2019 |
End | 12/2019 |
Description | Keele University Academic Returners' Fund |
Amount | £3,256 (GBP) |
Organisation | Keele University |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2020 |
End | 08/2020 |
Description | MICA: Moving From Autologous to Allogeneic Cell Therapy: Developing Up-Scale GMP Protocols for Orthopaedics. |
Amount | £450,000 (GBP) |
Funding ID | MR/S015167/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2019 |
End | 11/2021 |
Description | MICROSCOPIC ASSESSMENT OF PATIENT SAMPLES FOR RESEARCH STUDIES CONDUCTED AT THE RJAH ORTHOPAEDIC HOSPITAL NHS FOUNDATION TRUST |
Amount | £16,000 (GBP) |
Funding ID | OL41 |
Organisation | Institute of Orthopaedics |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2021 |
End | 08/2021 |
Description | MRC Pathfinder |
Amount | £478,192 (GBP) |
Funding ID | MR/N02706X/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2016 |
End | 12/2020 |
Description | PhD Studentship to perform bioinformatics and analyse RNASeq data from ASCOT trial |
Amount | £60,000 (GBP) |
Organisation | Keele University |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2019 |
End | 12/2022 |
Description | Renewal of Arthritis Research UK Tissue Engineering Centre |
Amount | £190,000 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 04/2021 |
Description | Transcriptome analysis of the Umbilical Cord-Mesenchymal Stromal Cells' therapeutic response to inflammation, with a view to banking the most potent cells for allogeneic therapy. |
Amount | £9,890 (GBP) |
Funding ID | RPG178 |
Organisation | Institute of Orthopaedics |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
Description | Transcriptomic, Proteomic and Bioinformatics Analyses of Cell-Based Therapies for Cartilage Injuries in Humans |
Amount | £144,418 (GBP) |
Funding ID | 22921 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2022 |
End | 10/2026 |
Description | ARUK Tissue Engineering Centre |
Organisation | Newcastle University |
Department | Newcastle University Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Co-investigator in this collaboration and leading the clinical trials section. |
Collaborator Contribution | Obtaining MIA (IMP) for a CTA by the MHRA trial of autologous chondrocytes versus Mesenchymal Stem Cells |
Impact | Various presentations and publications |
Start Year | 2011 |
Description | Arthritis Research UK Biomechanics and Bioengineering Centre Grant (University of Cardiff) |
Organisation | Cardiff University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Richardson invited to join the current Centre International Scientific Advisory Board as a research-oriented Orthopaedic Surgeon. |
Collaborator Contribution | Sharing of knowledge |
Impact | None |
Start Year | 2017 |
Description | OA Tech+ Network |
Organisation | Cardiff University |
Department | School of Engineering |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | To be one of ~90 individuals around the UK with an interest and keenness in contributing to forming a network which aims to identify challenges and knowledge gaps, support and drive multidisciplinary collaborations in UK osteoarthritis research, form the basis for high-level grant funding and high impact papers and, ultimately, improve diagnosis, treatment and bring novel therapies to market. Professor Roberts is Theme Lead of 'Novel experimental technology for human / animal in vivo and in vitro studies in the lab, clinic and beyond'. We organised the 1st major event for this grant (following the start-up meeting) with a conference in Oswestry on 'the Contribution of Technology on Stratification of OA' and also hosted a sandpit related to this. |
Collaborator Contribution | Please see the aims as detailed above. |
Impact | A start up meeting was held earlier this month. We organised the 1st major event for this grant (following the start-up meeting) with a conference in Oswestry on 'the Contribution of Technology on Stratification of OA'. |
Start Year | 2016 |
Description | Versus Arthritis Tissue Engineering and Joint Preservation Centre |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Other partners in the TEC include Aberdeen, Newcastle, York and Birmingham Universities. Our contribution is both clinical and scientific input, in being able to study human cells, tissues and patients and in developing an allogeneic source of MSCs |
Collaborator Contribution | Expert knowledge of MSCs. materials, extracellular vesicles, cell characterisation etc |
Impact | Many outputs in the form of meeting presentations, papers, chapters, grants and collaborative muti-disciplinary research. |
Start Year | 2010 |
Title | ASCOT |
Description | Autologous Cell Implantation is being used to treat chondral/osteochondral defects. ASCOT is trialling and comparing 3 different cell populations: Chondrocytes Mesenchymal Stem Cells (MSCs) Chondrocytes and MSCs combined |
Type | Therapeutic Intervention - Cellular and gene therapies |
Year Development Stage Completed | 2014 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Several of the categories above could be true - but we will not know until the trial is completed. |
URL | http://www.isrctn.com/ISRCTN98997175 |
Title | Autologous Chondrocytes |
Description | Funded by the NHS and ARUK and the Orthopaedic Institute Ltd as a Licenced Product under the MHRA Hospital Exemption Scheme. |
Type | Therapeutic Intervention - Cellular and gene therapies |
Current Stage Of Development | Late clinical evaluation |
Year Development Stage Completed | 2010 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Improved quality of life and shown evidence that it is a cost effective treatment. |
URL | http://www.isrctn.com/ISRCTN48911177 |
Description | 11th Oswestry Cartilge Course |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Focussed Symposium on current techniques and regulatory requirements in cell cell therapy. |
Year(s) Of Engagement Activity | 2017 |
Description | 2-day Delphi meeting on using technology to stratify osteoarthritis patients held at RJAH Orthopaedic Hospital, Keele University |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | wide discussions on the best use of technologies to aid stratification of patients with osteoarthritis |
Year(s) Of Engagement Activity | 2018 |
Description | BORS 2015 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture given by Professor Richardson summarising early results of ACTIVE and plans for ASCOT |
Year(s) Of Engagement Activity | 2015 |
Description | Cartilage Meeting (RJAH) 24th & 25th November 2016 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentations given by local and visiting faculty and delegates attended from various institutions undertaking cell therapy scientifically/clinically |
Year(s) Of Engagement Activity | 2016 |
Description | Cell Therapy Workshop (Eurocell) Sept 2015 RJAH |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Focussed workshop on Autologous chondrocyte culture techniques and regulatory requirements. |
Year(s) Of Engagement Activity | 2015 |
Description | External speaker at a Tissue Engineering Module in Cardiff University |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Undergraduate students |
Results and Impact | A lecture was given to ~60 undergraduate students on different degree courses. On more thank one occasion it has resulted in our group being approached by interested undergraduate students who wish to undertake a PhD with us. |
Year(s) Of Engagement Activity | 2009,2010,2011,2012,2013,2014,2015,2016,2017,2018,2019,2020 |
Description | Health feature on ACI in The Times |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | The Times wrote an article on ACI and cell therapy for cartilage repair after interviewing Sally Roberts about the treatment in RJAH, Oswestry. There were several enquiries from potential patients following this. |
Year(s) Of Engagement Activity | 2020 |
Description | Health feature on ACI in The Times |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | The Times wrote an article on ACI and cell therapy for cartilage repair after interviewing Sally Roberts about the treatment in RJAH, Oswestry. There were several enquiries from potential patients following this. |
Year(s) Of Engagement Activity | 2020 |
Description | Institutional Away Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts organised the Institutional Away Day for the School of Pharmacy and Bioengineering (PhaB) held at Keele University. Up to 50 members of the institution attended and participated in a number of oral presentations about the research occuring within the institution. |
Year(s) Of Engagement Activity | 2019 |
Description | International Cartilage Course |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Type Of Presentation | paper presentation |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 8th Oswestry Cartilage Repair Meeting 2nd & 3rd May 2013 at RJAH Orthopaedic Hospital, Oswestry, Shropshire. 48 delegates 13 Trade Stands 26 Speakers (local, national and international) 9th Oswestry Cartilge Repair Meeting 2014 at RJAH Orthopaedic Hospital, Oswestry, Shropshire 54 Delegates 4 Companies 24 Speakers (local, national and international) Discussion and updates on work being undertaken locally, nationally and internationally on tissue engineering. 9th Oswestry Cartilage Repair Meeting planned for 1st and 2nd May 2014. Further meetings will be held and hope to run them every other year. |
Year(s) Of Engagement Activity | Pre-2006,2006,2009,2014 |
Description | Interview for national TV programme |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | ACI at RJAH Orthopaedic Hospital was featured on the One Show, November 2019. The PI (Sally Roberts) and surgeon (Mr P Gallacher) who commonly performs ACI in RJAH were both interviewed alongside a patient who had undergone the procedure. The programme has broad coverage and raised some interest in the treatment and the hospital. |
Year(s) Of Engagement Activity | 2019 |
Description | Invited Speaker at the UK Regenerative Medicine Platform joint meeting of 2 hubs, 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Talk title: Clinical Trials for Cartilage and Bone Repair: challenges and outcomes |
Year(s) Of Engagement Activity | 2016 |
Description | Lecture given by Professor Roberts at Exeter meeting "Biomarkers for early stage OA and experimental treatment programmes" |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts presented a plenary talk on cell therapy for cartilage repair in early OA - wet and imaging biomarkers. Started a collaboration with a new colleague. |
Year(s) Of Engagement Activity | 2018 |
Description | Market Analysis of ACI |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Workshop set up with Edward Draper, from a company called Ortheia, to set up the Market Analysis of ACI project, for which funding was granted from Keele University earlier in 2019. |
Year(s) Of Engagement Activity | 2019 |
Description | Old Oswestrian Meeting |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts was invited to speak at the Old Oswestrian meeting discussing Professor Richardson's contribution to cell therapy and research |
Year(s) Of Engagement Activity | 2019 |
Description | PhD Viva, Sheffield University student |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | S Roberts was invited as an external examiner for a PhD thesis for a student in Sheffield University |
Year(s) Of Engagement Activity | 2019 |
Description | Presentation (Prof Richardson) to AROS, Denmark |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture and discussion by Professor Richardson on cell therapy for early arthritis "Personalising cell based treatments for cartilage repair" |
Year(s) Of Engagement Activity | 2015 |
Description | Presentation (Prof Roberts) at AROS, Denmark |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture and discussion by Professor Sally Roberts "Challenges of Cell Therapy for Intervertebral disc regeneration" |
Year(s) Of Engagement Activity | 2015 |
Description | Presentation at Outreach Evening at Keele University by Professor Richardson |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Professor Richardson invited to give presentation at Outreach Evening organised by Keele Univesity which was aimed at 6th Form Students and the general public. |
Year(s) Of Engagement Activity | 2017 |
Description | Presentation at Outreach Evening at Keele University by Professor Richardson |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Professor Richardson invited to give presentation at Outreach Evening organised by Keele Univesity which was aimed at 6th Form Students and the general public. |
Year(s) Of Engagement Activity | 2017 |
Description | Presentation by Prof James Richardson at Qatar Research Day |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited to give presentation on cell therapy at Qatar Research Day 2017 |
Year(s) Of Engagement Activity | 2017 |
Description | Presentation by Prof James Richardson at Qatar Research Day |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited to give presentation on cell therapy at Qatar Research Day 2017 |
Year(s) Of Engagement Activity | 2017 |
Description | Presentation to Local Polymyalgia Rheumatica Giant Cell Arteritis Group, Leebotwood, by Prof Sally Roberts and Dr Helen McCarthy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Other audiences |
Results and Impact | Invited by the Group Chairperson to give a talk on cell therapy at one of their monthly Group meetings. |
Year(s) Of Engagement Activity | 2017 |
Description | Presentation to Local Polymyalgia Rheumatica Giant Cell Arteritis Group, Leebotwood, by Prof Sally Roberts and Dr Helen McCarthy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Other audiences |
Results and Impact | Invited by the Group Chairperson to give a talk on cell therapy at one of their monthly Group meetings |
Year(s) Of Engagement Activity | 2017 |
Description | Professor Roberts invited as a plenary lecturer in a session at the BORS meeting, Sept 2018 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts gave a talk entitled 'Biological phenotyping of osteoarthritis - can technology help?' |
Year(s) Of Engagement Activity | 2018 |
Description | Professor Roberts invited as a plenary speaker at a Spherox/ACI users meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts gave a talk entitled: The medical need of ACI in the UK |
Year(s) Of Engagement Activity | 2018 |
Description | Professor Roberts invited as plenary speaker at the Inaugural anniversary meeting of the Vietnamese Stem Cell Centre, Hanoi |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts gave a talk entitled 'Cell therapy in orthopaedics; a 20 year journey' |
Year(s) Of Engagement Activity | 2017 |
Description | Professor Roberts invited to give a talk on 'Cell therapy trials versus arthritis'; PPI group meeting in Newcastle |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | A talk to the general public about treatment preventing OA |
Year(s) Of Engagement Activity | 2018 |
Description | Professor Roberts was an Invited Speaker at the ICRS World Congress, Italy, 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Talk title: Structural Outcomes of Cellular Therapy for Cartilage Repair |
Year(s) Of Engagement Activity | 2017 |
Description | Professor Roberts was an invited Speaker at the British Society for Gene and Cell Therapy Annual Conference and UK Regenerative Medicine Platform Joint Meeting, Wales, April 2017. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Talk title: Cell therapy for cartilage and bone repair: A small UK manufacturer's update' |
Year(s) Of Engagement Activity | 2017 |
Description | RJAH Research Public Open Day 2017 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Open Day prior to 2017 RJAH Research Day with tours of research departments, presentations and display of research posters. Sharing information about research studies within organisation to general public and staff. |
Year(s) Of Engagement Activity | 2017 |
Description | RJAH Research Public Open Day 2017 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Open Day prior to 2017 RJAH Research Day with tours of research departments, presentations and display of research posters. Sharing information about research studies within organisation to general public and staff. |
Year(s) Of Engagement Activity | 2017 |
Description | S Roberts Invited Lecture at the ICRS 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Sally Roberts was invited to give a lecture entitled "A Scientist's Best & Worst Experiences Related to Cell Therapy for Joint Preservation" during the My Best & Worst Experiences in Pre-clinical and Clinical Joint Repair session. |
Year(s) Of Engagement Activity | 2019 |
Description | S Roberts oral presentation at ICRS 2019 on behalf of H. McCarthy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | S Roberts gave the oral presentation for the abstract submitted by H. McCarthy entitled "The Natural Repair of Articular Cartilage in Humans: An Immunohistological Study" |
Year(s) Of Engagement Activity | 2019 |
Description | S Roberts oral presentation at ICRS 2019 on behalf of J. Perry |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Sally Roberts gave the oral presentation for the abstract submitted by J. Perry entitled "The Suitability Of Pre-Operative Magnetic Resonance Imaging In Predicting Accurate Cartilage Defect Sizes For Treatment With Cell Therapy" |
Year(s) Of Engagement Activity | 2019 |
Description | S Roberts oral presentation at ICRS 2019 on behalf of T. Hopkins |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Sally Roberts gave the oral presentation for the abstract submitted by T. Hopkins entitled "The Effect of Affect: Does a Patient's Outlook Influence Their Recovery?" |
Year(s) Of Engagement Activity | 2019 |
Description | Sandpit held in RJAH Orthopaedic Hospital, Keele University (as part of OATech+ Network) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Sandpit meeting for small pump-priming projects |
Year(s) Of Engagement Activity | 2018 |
Description | Steering Committee for Medical Science Society at local secondary school |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Professor Sally Roberts gives talks and sits on the Steering Committee for the Medical Science Society at local secondary school |
Year(s) Of Engagement Activity | 2015 |
Description | Stem Cells In Regenerative Medicine (organised and hosted in Oswestry) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This interactive one day meeting focussed on the mechanisms of action of stem cells in vivo, their interaction with the immune system and the immunological barriers to regenerative medicine. Approximately 60-80 delegates attended. |
Year(s) Of Engagement Activity | 2015 |
Description | Turbo talk at TCES |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited turbo talk for a potential prize-winning poster |
Year(s) Of Engagement Activity | 2018 |
Description | Visit Leukerband Clinic, Switzerland 19th & 20th January 2017 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Prof Richardson was invited by Leukerband Clinic, Switzerland, to give two presentations relating to cell therapy research and clinical application for practitioners within their locality. |
Year(s) Of Engagement Activity | 2017 |